The cancer drug imatinib created a stir a few years ago when it rescued leukemia patients who had failed to improve on other treatments. Now, in the first large-scale test of the drug in people newly diagnosed with chronic myeloid leukemia (CML), imatinib has stopped or reversed the disease in nearly all patients receiving it.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.